Benzinga | Jan 4, 2022 08:03AM EST

Applied DNA Receives New York State Department Of Health Conditional Approval For Linea 2.0 COVID-19 Assay As Laboratory Developed Test

Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs (ADCL), has received conditional approval from the New York State Department of Health (NYSDOH) for its Linea(tm) 2.0 Assay (the "Linea 2.0 Assay") as a Laboratory Developed Test (LDT), pending a final review of the assay's validation data by NYSDOH. With the conditional approval, ADCL can immediately employ the Linea 2.0 Assay for COVID-19 testing to support New York State-based safeCircle(tm) clients for the diagnostic testing of COVID-19. The Linea 2.0 Assay is conditionally approved for individual and pooled (up to 5-samples) testing.